Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome

Adler, Gail K.; Kinsley, Brendan; Hurwitz, Shelley; Mossey, Christopher; Goldenberg, Don L.

doi:10.1016/s0002-9343(99)00074-1

Cited by 179 publications

(114 citation statements)

References 25 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…In humans circadian rhytmicity is originated by hypothalamus and FM patients have a disturbed hypothalamic cortical adrenal axis [42,43]. Many studies show that FM patients have decreased levels of growth hormone (GH) [44,45] and its metabolites, particularly during the night [46].…”

Section: Abnormalities Of Circadian Rhythm and Biochemical Alterationmentioning

confidence: 99%

Sleep Disorders in Fibromyalgia Syndrome

Rizzi¹,

Cristiano²,

Frassanito³

et al. 2016

J Pain Relief

View full text Add to dashboard Cite

Section: Abnormalities Of Circadian Rhythm and Biochemical Alterationmentioning

confidence: 99%

Sleep Disorders in Fibromyalgia Syndrome

Rizzi¹,

Cristiano²,

Frassanito³

et al. 2016

J Pain Relief

View full text Add to dashboard Cite

“…Perhaps the most consistent finding regarding autonomic function is that patients with FM have an impaired catecholamine response to a variety of different stressors; in different studies, exercise, muscle contraction, and hypoglycemia led to sympathetic responses that were diminished when compared with control groups [45][46][47]. In a study by van Denderen [45], submaximal exercise, which induces primarily a sympathoneural response, led to an attenuated norepinephrine response in patients with FM.…”

Section: Biochemical Markersmentioning

confidence: 99%

Sympathetic nervous system function in fibromyalgia

Petzke

Clauw

2000

Curr Rheumatol Rep

View full text Add to dashboard Cite

This review focuses on studies of the sympathetic nervous system in fibromyalgia (FM). First, a brief review of the sympathetic system, and its relationship to the human stress response, is outlined. Then various studies of functional assessment of sympathetic function in FM are highlighted. Certain methods of assessment (eg, heart rate variability, biochemical, and psychophysical responses to various stressors) that we believe to be of specific importance for future research are discussed in greater detail. Finally, findings on autonomic function in related disorders--specifically, chronic fatigue syndrome, irritable bowel syndrome, and migraine--will be briefly presented.

show abstract

“…Clinical evidence supports activation of the SNS in autoimmune patients; serial determinations of cardiovascular measures indicate that the SNS activity reflects activity of inflammation and clinical course of autoimmune diseases [79, 80]. CRH cell bodies in extrahypothalamic sites, the amygdala in concert with the aforementioned brainstem nuclei, are critical in the activation of the SNS [26,] and CRHR1 antagonists have been demonstrated in in vivo studies to diminish the SNS output in primates [81] and rodents [82].…”

Section: Inflammation and Autoimmune Diseasementioning

confidence: 99%

Nonpeptide Corticotropin-Releasing Hormone Receptor Type 1 Antagonists and Their Applications in Psychosomatic Disorders

Contoreggi¹,

Rice²,

Chrousos³

2004

Neuroendocrinology

View full text Add to dashboard Cite

Overproduction of corticotropin-releasing hormone (CRH) and stress system abnormalities are seen in psychiatric diseases such as depression, anxiety, eating disorders, and addiction. Investigations of CRH type 1 receptor (CRHR1) nonpeptide antagonists suggest therapeutic potential for treatment of these and other neuropsychiatric diseases. However, overproduction of CRH in the brain and on its periphery and disruption of the hypothalamic-pituitary-adrenal axis are also found in ‘somatic’ disorders. Some rare forms of Cushing’s disease and related pituitary/adrenal disorders are obvious applications for CRHR1 antagonists. In addition, however, these antagonists may also be effective in treating more common somatic diseases. Patients with obesity and metabolic syndrome who often have subtle, but chronic hypothalamic-pituitary-adrenal hyperactivity, which may reflect central dysregulation of CRH and consequently glucocorticoid hypersecretion, could possibly be treated by administration of CRHR1 antagonists. Hormonal, autonomic, and immune aberrations are also present in chronic inflammatory, autoimmune, and allergic diseases, with considerable evidence linking CRH with the observed abnormalities. Furthermore, autonomic dysregulation is a prominent feature of common gastrointestinal disorders, such as irritable bowel syndrome and peptic ulcer disease. Patients with irritable bowel syndrome and other gastrointestinal disorders frequently develop altered pain perception and affective symptoms. CRH acts peripherally to modulate bowel activity both directly through the autonomic system and centrally by processing viscerosensory and visceromotor neural signals. This review presents clinical and preclinical evidence for the role of CRH in the pathophysiology of these disorders and for potential diagnostic and therapeutic applications of CRHR1 antagonists. Recognition of a dysfunctional stress system in these and other diseases will alter the understanding and treatment of ‘psychosomatic’ disorders.

show abstract

Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome

Cited by 179 publications

References 25 publications

Sleep Disorders in Fibromyalgia Syndrome

Sleep Disorders in Fibromyalgia Syndrome

Sympathetic nervous system function in fibromyalgia

Nonpeptide Corticotropin-Releasing Hormone Receptor Type 1 Antagonists and Their Applications in Psychosomatic Disorders

Contact Info

Product

Resources

About